Fate Therapeutics (FATE) Misses Q2 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.18 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion